This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / … (NCT07017179) | Clinical Trial Compass
RecruitingPhase 2
This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight
China871 participantsStarted 2025-05-20
Plain-language summary
This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18 to 55 years.
✓. BMI ≥ 27 kg/m2.
✓. Stable body weight for 3 months prior to screening.
✓. Male and female (Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies).
✓. Participants should refrain from blodd donation throughout the sub-study, including the follow-up period.
✓. Negative pregnancy test at screening and randomisation for FOCBP and must not be breastfeeding.
Exclusion criteria
✕. Have received prescription medication or non-prescription medication for weight loss within the last 3 months prior to screening.
✕. History of type 1 or type 2 diabetes mellitus or symptoms indicative of insulinopenia or poor glucose control.
✕. Treatment with diabetes medication in past 3 months prior to screening.
. Significant hepatic disease (except for non-alcoholic steatohepatitis or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: